Del Brutto should not be surprised by the results of our clinical trial of treatment of neurocysticercosis (NC).1 A series of articles were published in JAMA to "help physicians translate the results of medical research into clinical practice."2 In one of them, the authors state that "to the surprise of many and the indignation of a few," well-conducted randomized clinical trials have contradicted the results of less rigorous studies supporting therapies previously considered "standard" practice.3
To address comments related to the sequence of our studies, we must provide a brief background for the current report. In January 1984, we received support from the Consejo Nacional de Universidades y Escuelas Politécnicas del Ecuador (CONUEP), the institution responsible for scientific research in our country, for a project titled "Clinical Aspects of Neurocysticercosis in Ecuador." In this project, we performed a retrospective review of cases treated for NC between 1984
Carpio A, Santillán F, León P, Flores C, Hauser WA. Is the Course of Neurocysticercosis Modified by Treatment With Anthelmintic Agents?-Reply. Arch Intern Med. 1997;157(1):129–130. doi:10.1001/archinte.1997.00440220134018
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.